Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.

Lucas CM., Scott LJ., Carmell N., Holcroft AK., Hills RK., Burnett AK., Clark RE.

PP2A inhibition occurs in AML by 2 different pathways: CIP2A in normal karyotype patients and SETBP1 in adverse karyotype patients. AKTS473 phosphorylation is a predictor of survival, and diagnostic levels of AKTS473 could be a novel biomarker in AML.

More information Original publication

DOI

10.1182/bloodadvances.2017013615

Type

Journal article

Publication Date

2018-05-08T00:00:00+00:00

Volume

2

Pages

964 - 968

Total pages

4

Keywords

Adult, Autoantigens, Biomarkers, Tumor, Carrier Proteins, Female, Humans, Intracellular Signaling Peptides and Proteins, Leukemia, Myeloid, Acute, Male, Membrane Proteins, Middle Aged, Nuclear Proteins, Phosphorylation, Protein Phosphatase 2, Proto-Oncogene Proteins c-akt